Bristol-myers Company

Bristol-myers Squibb Compnay

Other

Kyoichiro Saitoh

Masataka Konishi

Koji Tomita

Takeo Miyaki

Toshikazu Oki

Mitsuaki Tsunakawa

Hiroshi Kawaguchi

Hiroaki Ohkuma

Maki Nishio

Kozo Tomatsu

Masami Hatori

Masatoshi Kakushima

Yosuke Sawada

Tamotsu Furumai

Seikichi Kobaru

Chiharu Ikeda

Haruaki Yamamoto

Nahomi Oda

The present invention relates to novel antifungal antibiotics herein designated as pradimicin L and pradimicin FL, and derivatives thereof. Pradimicins L and FL are produced by Actinomadura verrucosospora subsp. neohibisca strain R103-3, ATCC No. 53930.

Pradimicins l and fl, and derivatives thereof

The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960-producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).

Production of pradimicin antibiotics

The novel antitumor antibiotic designated herein as dynemicin C is produced by fermentation of Micromonospora chersina M956-1 mutant F1085 (ATCC-55077). Dynemicin C and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors.

Dynemicin C antibiotic, its triacetyl derivative and pharmaceutical

Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.

Antifungal antibiotics

A novel antibiotic complex designated herein as BBM-1675 complex is produced by fermentation of certain novel strains of Actinomadura verrucosospora. The complex may be separated into two major components, BBM-1675 A.sub.1 and A.sub.2, and four minor components, BBM-1675 A.sub.3, A.sub.4, B.sub.1 and B.sub.2, and such components exhibit both antimicrobial activity and antitumor activity.

BBM-1675, a new antitumor antibiotic complex

Boholmycin antibiotic is prepared by fermentation of Streptomyces hygroscopicus H617-25 (ATCC No. 53240) in a nutrient medium preferably comprising glycerol, bacto-liver, cornsteep liquor, ammonium sulfate, sodium chloride and calcium carbonate. The antibiotic and pharmaceutically acceptable salts and hydrates thereof and compositions containing these are effective against Gram-positive, Gram-negative and acid-fast bacteria and against bacterial strains which are resistant to previously known aminoglycoside antibiotics and are useful to treat bacterial infections in mammals.

Boholmycin antibiotic

The novel antibiotics boxazomycin A and B, which have the formula: ##STR1## wherein R is --CH.sub.2 OH for boxazomycin A; and R is --CH.sub.3 for boxazomycin B. These new antibiotics, which are produced by cultivating a novel strain of Pseudonocardia (ATCC 53205), inhibit growth of aerobic Gram-positive bacteria and anaerobes with enhanced activity observed in acidic medium.

Boxazomycin A and B, new antibiotics containing benzoxazole nucleus

Antitumor antibiotic complex

A novel antibiotic complex designated herein as BBM-1675 complex is produced by fermentation of certain novel strains of Actinomadura verrucosospora. The complex may be separated into two major components, BBM-1675 A.sub.1 and A.sub.2, and four minor components, BBM-1675 A.sub.3, A.sub.4, B.sub.1 and B.sub.2, and such components exhibit antimicrobial activity and also antitumor activity in certain mouse tumor systems.

Growing community of inventors

Zushi, Japan

Kyoichiro Saitoh